Table 2. Incidence rate, crude and adjusted hazard ratios for injury among the sampled subjects.
| Presence of injury during the 90-day follow-up period | Total (n = 154,072) | Subjects who were prescribed Zolpidem (n = 77,036) | Comparison subjects (n = 77,036) | |||
| n, % | n, % | n, % | ||||
| Injury | 6,974 | 4.5 | 4,689 | 6.1 | 2,285 | 3.0 |
| Incidence rate per 100 person-years (95% CI) | 18.11 (17.69–18.54) | 24.35 (23.66–25.05) | 11.86 (11.39–12.36) | |||
| Crude HRa (95% CI) | – | 2.12*** (2.02–2.23) | 1.00 | |||
| Adjusted HRb (95% CI) | – | 1.83*** (1.73–1.94) | 1.00 | |||
Notes: ***indicates p<0.001.
Hazard ratio was calculated by using stratified Cox proportional regression (stratified on sex and age group).
Adjustment for patient’s monthly income, urbanization level, geographic region, cardiac arrhythmias, congestive heart failure, valvular disease, pulmonary circulation disorders, periphreal vascular disorders, hypertension, paralysis, coagulopathy, other neurological disorders, chronic pulmonary disease, diabetes uncomplicated, diabetes complicated, hypothyroidism, renal failure, liver disease, peptic ulcer disease excluding bleeding, solid tumor without metastatsis, rheumatoid arthritis, fluid and electrolyte disorders, blood loss anemia, deficiency anemias, alcohol abuse, drug abuse, psychoses, depression, AIDS, lymphoma, metastatic cancer, obesity, weight loss, and propensity score.